宁心宝胶囊联合普罗帕酮治疗室性心律失常的临床研究
|
摘要
目的观察宁心宝胶囊联合普罗帕酮治疗室性心律失常的安全性与有效性。方法选取2016年7月—2017年7月于重庆市巴南区人民医院治疗的室性心律失常患者151例,随机分成对照组(75例)和治疗组(76例)。对照组患者口服盐酸普罗帕酮片,6片/次,3次/d;治疗组患者在对照组基础上口服宁心宝胶囊,2粒/次,2次/d。两组患者连续治疗2个月。观察两组患者临床疗效,同时比较治疗前后两组患者动态心电图指标、心功能指标和不良反应情况。结果治疗后,对照组和治疗组临床有效率分别为85.33%和96.05%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者QRS波时限、室性早搏及短阵室速较治疗前显著降低(P<0.05),且治疗组这些动态心电图指标明显低于对照组(P<0.05)。治疗后,两组患者6min步行距离和左心室射血分数(LEVF)水平较治疗前显著升高(P<0.05),脑尿钠肽(BNP)水平显著降低(P<0.05),且治疗组这些心功能指标明显好于对照组(P<0.05)。治疗期间,治疗组患者药物不良反应发生率为3.95%,显著低于对照组患者的14.67%,两组比较差异具有统计学意义(P<0.05)。结论宁心宝胶囊联合普罗帕酮治疗室性心律失常效果显著、安全性高,且能够显著改善患者心功能,具有一定的临床推广应用价值。
Objective To observe the safety and efficacy of Ningxinbao Capsules combined with propafenone in treatment of ventricular arrhythmia. Methods Patients(151 cases) with ventricular arrhythmia in Banan People's Hospital of Chongqing from July 2016 to July 2017 were randomly divided into control(75 cases) and treatment(76 cases) groups. Patients in the control group were po administered with Propatenone Hydrochloride Tablets, 6 tablets/time, three times daily. Patients in the treatment group were po administered with Ningxinbao Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the dynamic electrocardiogram indicators, the cardiac function indicators and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 85.33% and 96.05% respectively, and there were differences between two groups(P <0.05). After treatment, the QRS duration, premature ventricualr contraction and nonsustained ventricular tachycardia in two groups were significantly decreased(P < 0.05), and these dynamic electrocardiogram indicators in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the 6 min walking distance and LEVF levels in two groups were significantly increased(P < 0.05), but BNP levels were significantly decreased(P < 0.05), and these indicators in the treatment group were significantly better than those in the control group(P < 0.05). During the treatment, the adverse reactions rate in the treatment group was 3.95%, which was significantly lower than 14.67% in the control group, with significant difference between two groups(P <0.05). Conclusion Ningxinbao Capsules combined with propafenone in treatment of ventricular arrhythmia has remarkable effect and high safe, can significantly improve the heart function, which has a certain clinical application value.
Objective To observe the safety and efficacy of Ningxinbao Capsules combined with propafenone in treatment of ventricular arrhythmia. Methods Patients(151 cases) with ventricular arrhythmia in Banan People's Hospital of Chongqing from July 2016 to July 2017 were randomly divided into control(75 cases) and treatment(76 cases) groups. Patients in the control group were po administered with Propatenone Hydrochloride Tablets, 6 tablets/time, three times daily. Patients in the treatment group were po administered with Ningxinbao Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the dynamic electrocardiogram indicators, the cardiac function indicators and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 85.33% and 96.05% respectively, and there were differences between two groups(P <0.05). After treatment, the QRS duration, premature ventricualr contraction and nonsustained ventricular tachycardia in two groups were significantly decreased(P < 0.05), and these dynamic electrocardiogram indicators in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the 6 min walking distance and LEVF levels in two groups were significantly increased(P < 0.05), but BNP levels were significantly decreased(P < 0.05), and these indicators in the treatment group were significantly better than those in the control group(P < 0.05). During the treatment, the adverse reactions rate in the treatment group was 3.95%, which was significantly lower than 14.67% in the control group, with significant difference between two groups(P <0.05). Conclusion Ningxinbao Capsules combined with propafenone in treatment of ventricular arrhythmia has remarkable effect and high safe, can significantly improve the heart function, which has a certain clinical application value.
引文
[1]曹克将.室性心律失常的治疗进展[J].中华心律失常学杂志,2011,15(3):165-166.
[2]张新超,王珺.室性心律失常致心脏猝死的防治[J].中国临床医生杂志,2008,36(1):9-11.
[3]胡琛.抗心律失常药普罗帕酮[J].世界临床药物,1994,15(6):340-342.
[4]杨朝宽.侯淑彦.宁心宝胶囊治疗心律失常[J].中国新药与临床杂志,1990,9(5):278-280.
[5]葛均波.徐永健.内科学[M].第8版.北京:人民卫生出版社,2013:197-204.
[6]陈贵廷,薛赛琴.最新国内外疾病诊疗标准[M].北京:学苑出版社,1991:220-223.
[7]蒋文平,吴宁.室上性快速心律失常治疗指南[J].中华心血管病杂志,2005,33(1):2-15.
[8]杨宝峰,蔡本志.心律失常发病机制研究进展[J].国际药学研究杂志,2010,37(2):81-88.
[9]曹克将,陈椿.抗心律失常药物的应用进展[J].中国实用内科杂志,2007,27(1):14-17.
[10]陈国伟,柳俊.普罗帕酮在抗快速心律失常中的应用原则及经验[J].中国实用内科杂志,1999,19(9):518-519.
[11]李国平.虫草制剂治疗心血管病的临床及实验研究进展[J].中国中医药科技,2007,14(6):472-473.
[12]武美秀,张文博.常见心律失常的心电图诊断误区[J].心电与循环,2003,22(3):184-188.
[13]张策.分析脑钠肽与心律失常的内在关系[J].医疗装备,2016,29(6):105.
[2]张新超,王珺.室性心律失常致心脏猝死的防治[J].中国临床医生杂志,2008,36(1):9-11.
[3]胡琛.抗心律失常药普罗帕酮[J].世界临床药物,1994,15(6):340-342.
[4]杨朝宽.侯淑彦.宁心宝胶囊治疗心律失常[J].中国新药与临床杂志,1990,9(5):278-280.
[5]葛均波.徐永健.内科学[M].第8版.北京:人民卫生出版社,2013:197-204.
[6]陈贵廷,薛赛琴.最新国内外疾病诊疗标准[M].北京:学苑出版社,1991:220-223.
[7]蒋文平,吴宁.室上性快速心律失常治疗指南[J].中华心血管病杂志,2005,33(1):2-15.
[8]杨宝峰,蔡本志.心律失常发病机制研究进展[J].国际药学研究杂志,2010,37(2):81-88.
[9]曹克将,陈椿.抗心律失常药物的应用进展[J].中国实用内科杂志,2007,27(1):14-17.
[10]陈国伟,柳俊.普罗帕酮在抗快速心律失常中的应用原则及经验[J].中国实用内科杂志,1999,19(9):518-519.
[11]李国平.虫草制剂治疗心血管病的临床及实验研究进展[J].中国中医药科技,2007,14(6):472-473.
[12]武美秀,张文博.常见心律失常的心电图诊断误区[J].心电与循环,2003,22(3):184-188.
[13]张策.分析脑钠肽与心律失常的内在关系[J].医疗装备,2016,29(6):105.